Medical Health & Life Science Research News

Placenta growth factor therapeutics development for 2017 published by leading research firm

Medical Market Research

Placenta Growth Factor Pipeline and Therapeutics Development H1 2017 provides comprehensive information on the therapeutics under development for Placenta Growth Factor, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Placenta Growth Factor pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Sample copy is available at:…w-h2-2017/inquiry

According to the recently published report 'Placenta Growth Factor - Pipeline Review, H2 2017'; Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) pipeline Target constitutes close to 11 molecules. Out of which approximately 11 molecules are developed by Companies.

Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) - Placental growth factor is a protein encoded by the PGF gene. Placental growth factor (PGF) is a member of the VEGF (vascular endothelial growth factor).

It plays an important role in angiogenesis and endothelial cell growth, stimulating their proliferation and migration. It binds to the receptor FLT1/VEGFR-1.

PGF is also expressed in many other tissues, including the villous trophoblast. 

The report 'Placenta Growth Factor - Pipeline Review, H2 2017' outlays comprehensive information on the Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Placenta Growth Factor (Vascular Endothelial Growth Factor Related Protein or PGF) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 2, 3, 3 and 3 respectively.

Report covers products from therapy areas Ophthalmology, Metabolic Disorders and Oncology which include indications Diabetic Macular Edema, Wet (Neovascular / Exudative) Macular Degeneration, Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, Choroidal Neovascularization, Diabetic Retinopathy, Macular Edema, Medulloblastoma, Myopia, Neovascular Glaucoma, Non-Proliferative Diabetic Retinopathy (NPDR), Optic Neuropathy, Rectal Cancer, Retinal Vein Occlusion and Retinopathy.

Browse full Report at:…ne-review-h2-2017

Scope of this report:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Placenta Growth Factor. The pipeline guide reviews pipeline therapeutics for Placenta Growth Factor by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Placenta Growth Factor therapeutics and enlists all their major and minor projects. The pipeline guide evaluates Placenta Growth Factor therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects. The pipeline guide reviews latest news related to pipeline therapeutics for Placenta Growth Factor.
  • This research report can: Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Placenta Growth Factor. Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies. Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Placenta Growth Factor pipeline depth and focus of Indication therapeutics. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

News From

Market Insights ReportsMarket Insights Reports
Category: Market Research Publishers and RetailersCompany about: MarketInsightsReports is your single point market research source for all industries including pharmaceutical, chemicals and materials, energy resource, automobile, IT, technology and media, food and beverages, and consumer goods, among others.  
This email address is being protected from spambots. You need JavaScript enabled to view it.